{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:05:55Z","timestamp":1776755155489,"version":"3.51.2"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"crossref","award":["RTA5980011"],"award-info":[{"award-number":["RTA5980011"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["RTA5980011"],"award-info":[{"award-number":["RTA5980011"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193112","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T18:43:50Z","timestamp":1519238630000},"page":"e0193112","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-2149","authenticated-orcid":true,"given":"Waranya","family":"Rattanavipapong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thunyarat","family":"Anothaisintawee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"ref1","article-title":"Global health sector strategy on viral hepatitis, 2016\u20132021","year":"2016"},{"key":"ref2","unstructured":"Berger S. Infectious Diseases of Thailand: 2017 GIDEON Informatics2017."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"JP Messina","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"SL Chen","year":"2006","journal-title":"International journal of medical sciences"},{"key":"ref5","unstructured":"World Health Organization. 20th Expert Committee on the Selection and Use of Essential Medicines Geneva2015 [cited 2016 29th December]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/en\/<\/ext-link>."},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/S2214-109X(15)00156-4","article-title":"Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"I Andrieux-Meyer","year":"2015","journal-title":"The Lancet Global health"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"e0176503","DOI":"10.1371\/journal.pone.0176503","article-title":"Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India","volume":"12","author":"R Aggarwal","year":"2017","journal-title":"PLOS ONE"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12876-016-0506-4","article-title":"Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6","volume":"16","author":"N Kapol","year":"2016","journal-title":"BMC gastroenterology"},{"key":"ref9","article-title":"The consultation meeting on preliminary results the research project \u201cEconomic evaluation and budget impact analysis of chronic hepatitis C virus treatment\u201d on 2 March 2016","year":"2016"},{"issue":"Suppl 2","key":"ref10","first-page":"S53","article-title":"Handling Time in Economic Evaluation Studies","volume":"91","author":"U Permsuwan","year":"2008","journal-title":"J Med Assoc Thai"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"e0145953","DOI":"10.1371\/journal.pone.0145953","article-title":"Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naive Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis","volume":"10","author":"T Suwanthawornkul","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3350\/kjhep.2008.14.1.36","article-title":"Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C","volume":"14","author":"K-T Kim","year":"2008","journal-title":"The Korean journal of hepatology"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1478-3231.2005.01196.x","article-title":"A randomized trial of 24-vs. 48-week courses of PEG interferon \u03b1-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan","volume":"26","author":"ML Yu","year":"2006","journal-title":"Liver International"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses","volume":"136","author":"CJ Liu","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","article-title":"Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon \u03b1-2a and ribavirin","volume":"22","author":"JW Yu","year":"2007","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1086\/591252","article-title":"Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin","volume":"198","author":"J Fung","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1440-1746.2007.04834.x","article-title":"Peginterferon \u03b1-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients","volume":"22","author":"M Kuboki","year":"2007","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3350\/kjhep.2008.14.1.46","article-title":"Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C","volume":"14","author":"HJ Lee","year":"2008","journal-title":"The Korean journal of hepatology"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/592579","article-title":"Pegylated interferon-\u03b1-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial","volume":"47","author":"C-H Liu","year":"2008","journal-title":"Clinical infectious diseases"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"ML Yu","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"N Hayashi","year":"2014","journal-title":"Journal of hepatology"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"N Hayashi","year":"2014","journal-title":"Journal of gastroenterology"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"GR Foster","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"E Lawitz","year":"2013","journal-title":"The Lancet infectious diseases"},{"issue":"20","key":"ref25","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"E Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"M Rodriguez-Torres","year":"2013","journal-title":"Journal of hepatology"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"EJ Gane","year":"2015","journal-title":"Gastroenterology"},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"ref32","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref34","unstructured":"Report for consumer price index of THAILAND YEAR 2015 BASE YEAR 2011 [Internet]. Ministry of Commerce. 2015."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"The World Economic Outlook Database. (2016) The international monetary fund. The World Economic Outlook Database, Washington DC, USA.","DOI":"10.5089\/9781513519333.081"},{"key":"ref36","article-title":"Standard cost lists for health technology assessment","author":"A Riewpaiboon","year":"2011"},{"key":"ref37","article-title":"Rational use of peginterferon alfa (2a or 2b) and ribavirin for HCV genotype 1, 2, 3, 6","year":"2015"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vhri.2013.09.002","article-title":"Resource utilization and direct medical costs of chronic hepatitis C in Thailand: a heavy but manageable economic burden","volume":"3","author":"S Thongsawat","year":"2014","journal-title":"Value in Health Regional Issues"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1185\/030079907X188189","article-title":"The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin","volume":"23","author":"E Devine","year":"2007","journal-title":"Current medical research and opinion"},{"key":"ref40","article-title":"Cost utiliy analysis and budget impact analysis of chronic hepatitis c treatment","author":"P Weerayingyong","year":"2011"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","article-title":"Health state utilities associated with attributes of treatments for hepatitis C","volume":"16","author":"LS Matza","year":"2015","journal-title":"The European Journal of Health Economics"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"e0149362","DOI":"10.1371\/journal.pone.0149362","article-title":"Decreasing hepatitis C virus infection in Thailand in the past decade: evidence from the 2014 national survey","volume":"11","author":"R Wasitthankasem","year":"2016","journal-title":"PloS one"},{"key":"ref43","unstructured":"Chittmittrapap S, Akkarathamrongsin S, Thong VD, Avihingsanon A, Poovorawan Y, Tangkijvanich P. Comparison of Molecular Epidemiology and Severity of Liver Fibrosis between HCV Mono-infection and HIV\/HCV Co-infection in Thailand. EASL Special Conference on End-Stage Liver Disease- Multifaceted; Glasgow, United Kingdom; 2015."},{"key":"ref44","article-title":"The consultation meeting on the results of research project \u201cEconomic evaluation and budget impact analysis of chronic hepatitis C virus treatment\u201d on 21 April 2016","year":"2016"},{"key":"ref45","unstructured":"The Health Economic Working Group. Meeting of the Health Economic Working Group on 22 May 2013. Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand; 2013."},{"key":"ref46","article-title":"Thailand Practice Guideline for Management of Chronic Hepatitis B and C 2015","year":"2015"},{"issue":"9","key":"ref47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011821","article-title":"Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations","volume":"6","author":"S Coward","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"ref48","first-page":"310","article-title":"Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy","volume":"4","author":"SM Lynch","year":"2016","journal-title":"Journal of clinical and translational hepatology"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0373-9","article-title":"Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals","volume":"34","author":"J Chhatwal","year":"2016","journal-title":"PharmacoEconomics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T11:48:55Z","timestamp":1719834535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193112"}},"subtitle":[],"editor":[{"given":"Jee-Fu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193112","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]}}}